{"id":409920,"date":"2021-01-06T16:33:24","date_gmt":"2021-01-06T21:33:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409920"},"modified":"2021-01-06T16:33:24","modified_gmt":"2021-01-06T21:33:24","slug":"bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/","title":{"rendered":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>PALO ALTO, Calif., Jan.  06, 2021  (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio\u2019s board of directors granted six new employees restricted stock units for an aggregate of 4,126 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan).<\/p>\n<p>The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of directors in November 2019.<\/p>\n<p>\n        <strong>About BridgeBio<\/strong><br \/>\n        <br \/>BridgeBio a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Grace Rauh<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NLi5SPUi3mleRAc3Am4I6fD-_vRxP8W_dtIRWev-1L_TSM87WyVnVPW7rQBGnZGLEFDbcRhFKWrj75eWivlnwM_4NFjHmAHmToicPaU1ZBU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Grace.rauh@bridgebio.com<\/a>\u00a0<\/strong><br \/>(917) 232-5478<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>John Grimaldi, Burns McClellan<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0WayGBZYtkCXnoFVVsk7Wq2iJ3jeDFrCrZ1hGt-uqvWmQncscLgI3eI0_bd3A3p7ebeuwDxcxTu4XGJGb8qwdcM-U8Qx3ilKf-TD1YrXg4U=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jgrimaldi@burnsmc.com<\/a>\u00a0<\/strong><br \/>212-213-0006 ext. 362<\/p>\n<p>Source: BridgeBio Pharma, Inc.<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ff276b2b-d2f9-4bef-9cba-8676481d81b3\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio\u2019s board of directors granted six new employees restricted stock units for an aggregate of 4,126 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of directors in November 2019. About BridgeBio &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409920","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio\u2019s board of directors granted six new employees restricted stock units for an aggregate of 4,126 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of directors in November 2019. About BridgeBio &hellip; Continue reading &quot;BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T21:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2021-01-06T21:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/\"},\"wordCount\":227,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/\",\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=\",\"datePublished\":\"2021-01-06T21:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio\u2019s board of directors granted six new employees restricted stock units for an aggregate of 4,126 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of directors in November 2019. About BridgeBio &hellip; Continue reading \"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T21:33:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2021-01-06T21:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/"},"wordCount":227,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/","name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=","datePublished":"2021-01-06T21:33:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc5NSMzOTA3ODYxIzIxNTY5MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409920"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409920\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}